On June 30, 2020, Akouos Inc., a Boston-based precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, announced the closing of its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including 1,875,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for gross proceeds of $244.4 million, before underwriting discounts and commissions and offering expenses payable by Akouos. All shares were offered by Akouos.

The company’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “AKUS” on June 26, 2020.

The deal team representing Akouos was led by Rosemary Reilly and Molly Fox.